Outcomes in COVID-19 pacritinib studies

0 0.5 1 1.5+ All studies -28% 1 200 Improvement, Studies, Patients Relative Risk Mortality -28% 1 200 RCTs -28% 1 200 Late -28% 1 200 Pacritinib for COVID-19 c19early.org November 2025 Favorspacritinib Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] death 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Effect extraction pre-specified(most serious outcome) Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] death 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Effect extraction pre-specified(most serious outcome) Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] death 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Effect extraction pre-specified(most serious outcome) Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] death 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Effect extraction pre-specified(most serious outcome) Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] death 10/99 8/101 Improvement, RR [CI] Treatment Control Cafardi (DB RCT) -28% 1.28 [0.35-4.61] death 5/99 4/101 Cafardi (DB RCT) 25% 0.75 [0.43-1.32] progression 17/99 23/101 Cafardi (DB RCT) -6% 1.06 [0.66-1.70] progression 26/99 25/101 Cafardi (DB RCT) -17% 1.17 [0.76-1.81] no improv. 31/99 27/101 Pacritinib COVID-19 outcomes c19early.org November 2025 Favors pacritinib Favors control